Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device

Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market

Fineline Cube Mar 3, 2026
Company Deals

Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy

Fineline Cube Mar 3, 2026
Company Deals

ArkBio Partners with Qilu Pharma on Azstarys China Commercialization – ADHD Therapy Market Entry

Fineline Cube Mar 3, 2026
Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Fineline Cube Mar 3, 2026
Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Fineline Cube Mar 3, 2026
Company Digital

Xianju Pharmaceutical and Adamerck Grant Aspen China Rights to Aomeikesong Neuromuscular Reversal Agent

Fineline Cube Feb 10, 2026

Zhejiang Xianju Pharmaceutical Co., Ltd. (SHE: 002332) and Hangzhou Adamerck Pharmlabs Inc. have entered a...

Company Deals

Zhendong Pharmaceutical Secures China Promotion Rights to Ferring’s Sodium Picosulfate

Fineline Cube Feb 10, 2026

Shanxi Zhendong Pharmaceutical Co., Ltd. (SHE: 300158) has entered a strategic partnership with Ferring Pharmaceuticals...

Company Deals

GenAssist Therapeutic Partners with Indian DART Foundation on Duchenne Muscular Dystrophy Base Editing

Fineline Cube Feb 10, 2026

Suzhou GenAssist Therapeutic Co., Ltd. has signed a Memorandum of Understanding (MoU) with India’s Dystrophy...

Company Deals

Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million

Fineline Cube Feb 10, 2026

Foresee Pharmaceuticals has entered an exclusive global licensing agreement with Primevera Therapeutics, a German biotech...

Company Deals

Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market

Fineline Cube Feb 10, 2026

Formosa Pharmaceuticals, Inc. (TPE: 6838) has entered an exclusive licensing agreement with Samil Pharmaceuticals Co.,...

Company Deals

Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal

Fineline Cube Feb 10, 2026

Nanjing Hanxin Pharmaceutical Technology Co., Ltd. has entered a licensing agreement with Amphastar Pharmaceuticals, Inc....

Company Deals

Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million

Fineline Cube Feb 10, 2026

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) has entered a strategic licensing agreement with...

Company Deals

Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal

Fineline Cube Feb 10, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a licensing agreement with U-mab Biopharma, acquiring exclusive...

Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Fineline Cube Feb 10, 2026

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has entered a strategic licensing agreement with Qilu...

Company Deals

Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med

Fineline Cube Feb 10, 2026

Kintor Pharmaceutical Limited (HKG: 9939) has entered an exclusive marketing service agreement with Beijing Dekai...

Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026

Huadong Medicine Co., Ltd (SHE: 000963) announced a key milestone in its strategic collaboration with...

Company Deals

Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology

Fineline Cube Feb 10, 2026

Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) has entered a strategic partnership with Shanghai RAAS...

Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026

Delonix Bioworks announced that DX-104, its Group B meningococcal (MenB) vaccine candidate, has received clinical...

Company Medical Device

Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market

Fineline Cube Feb 9, 2026

Peijia Medical Ltd (HKG: 9996) announced it has submitted CE mark registration under the European...

Company

Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego

Fineline Cube Feb 9, 2026

Novartis AG (NYSE: NVS) held a groundbreaking ceremony for a state-of-the-art global biomedical research center...

Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Fineline Cube Feb 9, 2026

Sino Biopharmaceutical Ltd (HKG: 1177) announced completion of patient enrollment for the registrational Phase III...

Company Drug

Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma

Fineline Cube Feb 9, 2026

Kite Pharma, a Gilead Sciences (NASDAQ: GILD) subsidiary, announced that the U.S. Food and Drug...

Company Medical Device

Jenscare Scientific’s LuX-Valve Plus Wins FDA Nod for US Pivotal Trial in Tricuspid Regurgitation

Fineline Cube Feb 9, 2026

Jenscare Scientific Co., Ltd. (HKG: 9877) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

Hengrui Pharma’s HRS-4642 Wins Breakthrough Therapy Designation for KRAS G12D Pancreatic Cancer

Fineline Cube Feb 9, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS-4642, its KRAS G12D-targeting...

Company Drug

Pfizer’s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion

Fineline Cube Feb 9, 2026

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted...

Posts pagination

1 … 7 8 9 … 629

Recent updates

  • MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions
  • Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II
  • Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes
  • Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension
  • Xellsmart’s iPSC Neural Therapy Cleared by NMPA and FDA – First “Off‑the‑Shelf” Cell Therapy for MSA‑P Enters Clinic
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Medical Device

MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions

Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Company Drug

Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.